Searched for
BROVANA
Cipla Q3 preview: Up to 7% YoY uptick seen in revenue. Margins to fall on a YoY and sequential basisCipla's Q3FY25 revenue is expected to grow 3.1-7%, with profit estimates ranging from a 2.2% decline to 14% growth. Brokerages have differi...- Lupin to acquire established products in Europe, Canada from Sanofi for Rs 91 crLupin has acquired a portfolio of established products in Europe and Canada from Sanofi for a purchase consideration of EUR 10 million. The...
- Cipla stocks dive to 7-month low; here’s why bears are ruling the counterIf they are minor in nature, then it is unlikely to hurt sales from the unit. However, if the regulator found major deviations from good ma...
- Lupin inks pact to acquire two inhalation brands from Sunovion for USD 75 mnThe acquisition of these two brands will expand the company's inhalation product portfolio in the US and strengthen its presence in the res...
- Pharma stock that Jhunjhunwala exited in Q2 is now buzzing. Here's what analysts sayAce investor Rakesh Jhunjhunwala probably exited this counter in the second quarter, as his name was not among the shareholders holding ove...
- Cipla gets USFDA nod for inhalation productThe company has received final approval for its abbreviated new drug application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mc...
- Glenmark Pharma gets USFDA nod for inhalation productGlenmark Pharmaceuticals has received final approval by the United States Food and Drug Administration (USFDA) for Arformoterol Tartrate In...
- Neutral on Lupin, target price Rs 1320: Motilal OswalLupin Ltd., incorporated in the year 1983, is a Large Cap company (having a market cap of Rs 55707.38 Crore) operating in Pharmaceuticals s...
Load More